Existing drug offers targeted treatment for aggressive breast cancer
A new study claims palbociclib, an approved breast cancer drug, can treat an aggressive form of the cancer, bringing hope to thousands of afflicted women in the UK.
A new study claims palbociclib, an approved breast cancer drug, can treat an aggressive form of the cancer, bringing hope to thousands of afflicted women in the UK.
Eureka Therapeutics announced successful preclinical results from its InvisiMask Human Antibody Nasal Spray in mice, which offers protection against SARS-CoV-2 S pseudotyped virus infection for up to 10 hours.
Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio (NASDAQ: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the preclinical results for MRT5500, a mRNA-based vaccine candidate against SARS-CoV-2, the virus that causes COVID-19 disease.
Bold Therapeutics, a clinical-stage biopharmaceutical company, recently generated additional data supporting rapid clinical development of BOLD-100 as a novel antiviral.
ImmunityBio said that its human Ad5 vaccine candidate (hAd5 vaccine candidate), which is being developed for the prevention of Covid-19, has yielded positive preclinical results.
Catalent has collaborated with speciality pharmaceutical company Ennaid Therapeutics for the development of an oral and antiviral treatment for Covid-19 disease.
Vir Biotechnology and Alnylam Pharmaceuticals said that they have selected an investigational RNAi therapeutic called VIR-2703 which will be developed for targeting the SARS-CoV-2 genome for the treatment of Covid-19 (novel coronavirus).
Hoth Therapeutics has reached an agreement with Voltron Therapeutics to form a joint venture entity, to be named HaloVax, to commence preclinical studies for the development of vaccine prospects to prevent the Coronavirus (COVID-19) based upon VaxCelerate.
Israeli biopharmaceutical firm RedHill Biopharma has secured the US Food and Drug Administration (FDA) approval for Talicia (omeprazole magnesium, amoxicillin and rifabutin) for the treatment of Helicobacter pylori (H. pylori) infection in adults.
Neoleukin Therapeutics, a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced the completion of the previously disclosed merger transaction with Aquinox Pharmaceuticals.